Author

A. Mulero-Sanchez

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:benchmarking· 1 Assay:bulk RNA-seq· 1 Organism:human· 1 Organism:mouse· 1 Research Focus:perturbation response prediction· 1

Frequent Co-Authors

R. Bernards· 2 shared S. Mainardi· 2 shared A. Berninger· 1 shared A. Bosma· 1 shared A. Dekker· 1 shared A. Friskes· 1 shared A. van Oudenaarden· 1 shared A. Vidal· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

R. Bernards

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Paradoxical activation of oncogenic signaling as a cancer treatment strategy

M. H. Dias, A. Friskes, S. Wang, J. M. H. Fernandes Neto, F. v. Gemert, S. Mourragui, H. J. Kuiken, S. Mainardi, D. Alvarez-Villanueva, C. Lieftink, B. Morris, A. Dekker, E. v. Dijk, C. Papagianni, M. S. da Silva, , R. Bernards

This study shows that inhibiting PP2A and WEE1 together can kill colon cancer cells by causing DNA replication collapse and cell death, and that resistance to this treatment suppresses tumor growth.

bioRxiv · Feb 6, 2023Cancer Biology

Combined SHP2 and ERK inhibition for the treatment of KRAS-driven Pancreatic Ductal Adenocarcinoma

K. J. Ciecielski, A. Mulero-Sanchez, A. Berninger, L. R. Canas, A. Bosma, K. Gorgulu, N. Wu, K. N. Diakopoulos, E. Kaya-Aksoy, D. A. Ruess, D. Kabacaoglu, F. Schmidt, L. Heinemann, Y. Fan, B. Thijssen, , S. Mainardi

This paper investigates the combination of SHP2 and ERK inhibition as a treatment for KRAS-driven pancreatic ductal adenocarcinoma, showing synergistic anticancer effects and tumor regression in mouse models.

bioRxiv · Dec 14, 2021 · PreprintCancer Biology